Report Highlights

U.S. Tissue Transglutaminase Test Market Overview

The U.S. tissue transglutaminase test market reached USD 185 million in 2024 and is projected to reach USD 320 million by 2032 at a 7.1% CAGR, representing the primary serological testing modality for celiac disease diagnosis and dietary compliance monitoring across the U.S. clinical laboratory network. Tissue transglutaminase IgA antibody testing — the TTG-IgA test — is the first-line serological test recommended by the American Gastroenterological Association, the American College of Gastroenterology, and ESPGHAN for initial celiac disease evaluation in symptomatic patients, and its role as the diagnostic gatekeeper for the estimated 3.3 million Americans with celiac disease makes it a high-utility clinical test with both volume and value growth potential as underdiagnosis rates improve. The market is served by a combination of national clinical reference laboratories — Quest Diagnostics, Laboratory Corporation of America, and BioReference — that process the majority of physician-ordered TTG testing through centralised laboratory networks, and in-vitro diagnostic manufacturers including Bio-Rad, Inova Diagnostics, and Thermo Fisher Scientific whose immunoassay platform TTG test kits serve hospital-based laboratories that process testing in-house.

The market's growth is driven by the dual commercial opportunity of diagnostic testing — identifying the estimated 2.6 million undiagnosed celiac disease patients through improved clinical awareness and testing uptake — and monitoring testing — providing the periodic TTG-IgA assessment that confirms dietary compliance in the diagnosed celiac disease population and detects inadvertent gluten exposure before clinical symptoms recur. Each commercial dimension has distinct competitive dynamics: diagnostic testing volume is driven by physician ordering behaviour and requires clinical education investment, while monitoring testing volume is driven by diagnosed patient retention in gastroenterology care relationships and benefits from patient-initiated testing convenience through home-to-lab specimen submission services that direct-to-consumer laboratory platforms now provide.

Growth Drivers for U.S. Tissue Transglutaminase Test Market

Three demand drivers are sustaining the U.S. TTG test market's growth through 2032. The improvement in celiac disease clinical awareness — driven by gastroenterology society guideline promotion, celiac disease patient advocacy organisation campaigns, and the growing body of published evidence linking celiac disease to extraintestinal manifestations including iron deficiency anaemia, unexplained osteoporosis, peripheral neuropathy, and infertility — is generating incremental testing from primary care physicians who were historically under-testing symptomatic patients relative to guideline recommendations. Primary care physician ordering of TTG-IgA tests has increased at approximately 9% annually since 2021 as awareness campaigns reach non-gastroenterology providers who encounter the most common celiac disease presentations in their daily practice. The paediatric testing segment is growing fastest within the diagnostic testing category, as paediatric gastroenterologists' promotion of routine celiac screening in first-degree relatives of diagnosed patients and in children with type 1 diabetes — whose celiac disease co-prevalence is estimated at 5–10% — is generating systematic paediatric TTG testing programmes that produce recurring volume through annual monitoring in the identified positive population.

The direct-to-consumer laboratory testing market is creating a third growth pathway for TTG testing outside traditional physician-ordering channels. Platforms including Everlywell, Let'sGetChecked, and Labcorp OnDemand now offer consumer-accessible TTG-IgA testing panels — delivered through at-home specimen collection kits or direct walk-in laboratory visits without physician referral — that are reaching the consumer-initiated wellness testing segment motivated by personal dietary curiosity rather than physician-identified clinical indication. While consumer-initiated TTG testing generates diagnostic quality concerns when positive results are not followed by physician-guided biopsy confirmation, the volume contribution of consumer-initiated testing to total TTG market volume is growing at approximately 24% annually as DTC laboratory platforms expand their test menu and consumer awareness of gluten-related health impacts continues to grow through social media and food media channels.

Regulatory and Reimbursement Environment

The U.S. tissue transglutaminase test market's regulatory and reimbursement framework significantly shapes its commercial dynamics. TTG-IgA testing reimbursement under Medicare Part B is established through CPT code 86200 (cyclic citrullinated peptide antibody) and CPT code 86255 (fluorescent antinuclear antibody; screen, each pattern) — though TTG-specific coding has its own established codes whose reimbursement rates vary by testing setting and payer mix. Commercial health insurance coverage for TTG-IgA testing is broadly established when testing is ordered with appropriate clinical indication documentation, but coverage for population screening in asymptomatic individuals — including family members of celiac patients who are not symptomatic — varies by insurer and creates reimbursement uncertainty that reduces physician ordering of surveillance testing in lower-risk populations. The FDA's 510(k) pathway for Class II in-vitro diagnostic devices governs TTG test kit commercial availability, and the emergence of point-of-care TTG test 510(k) submissions from manufacturers including Simtomax and others is the regulatory development most likely to accelerate market volume growth by enabling same-visit celiac diagnosis in primary care settings.

CMS's Clinical Laboratory Fee Schedule annual update process directly determines the reimbursement economics for laboratory-performed TTG testing, and the sustained advocacy of the American Clinical Laboratory Association against proposed CLFS rate reductions is the policy process most closely watched by clinical laboratory operators whose TTG test volume is concentrated in Medicare-reimbursed patient populations. Private laboratory market participants including Quest and LabCorp negotiate commercial insurance TTG test rates through payer contract processes that typically offer rates 15–35% above CLFS levels for laboratories with preferred network status — a reimbursement premium that sustains margin economics despite volume discounting in national account contract structures.

Market Opportunities in U.S. Tissue Transglutaminase Test Market

The deamidated gliadin peptide antibody testing adjunct opportunity represents a clinical value expansion pathway for TTG test market participants. DGP-IgA and DGP-IgG antibody testing, recommended as adjunctive tests in IgA-deficient patients where TTG-IgA has reduced diagnostic sensitivity, is increasingly being offered as a panel supplement to TTG-IgA testing rather than as a sequential add-on — converting single-analyte TTG test orders into multi-analyte celiac panel orders with higher total revenue per requisition. Laboratory operators who develop comprehensive celiac serology panels — combining TTG-IgA, DGP-IgA, DGP-IgG, and total IgA — and market them to gastroenterology practices as complete first-visit celiac evaluation tools are capturing higher per-patient revenue than single-analyte TTG test operators without additional specimen collection burden on the ordering physician.

The population screening debate — whether routine TTG-IgA screening of the asymptomatic general population is clinically and economically justified — is the most commercially significant long-term demand catalyst for the U.S. TTG test market. Systematic review evidence increasingly supports population screening's ability to identify the 80% of celiac patients who remain undiagnosed and prevent the long-term health complications — osteoporosis, lymphoma, and infertility — that undiagnosed celiac disease causes. If the U.S. Preventive Services Task Force updates its currently insufficient evidence position on celiac disease screening to a positive recommendation — a development that the National Celiac Association is actively pursuing through systematic review submission processes — the resulting Medicare and commercial insurance coverage mandate for population celiac screening would transform the U.S. TTG test market from a clinical indication-based market to a population health screening market with demand characteristics that would multiply current testing volume by an estimated 4–6 times over a 5–7 year implementation period.

Market at a Glance

Leading Market Participants

• Quest Diagnostics
• Laboratory Corporation of America (Labcorp)
• Bio-Rad Laboratories
• Inova Diagnostics
• Thermo Fisher Scientific
• BioReference Laboratories
• Werfen Group (Instrumentation Laboratory)
• Simtomax
• Everlywell
• IDEXX Laboratories (human division)

Competitive Outlook for U.S. Tissue Transglutaminase Test Market

The U.S. TTG test market will reach USD 320 million by 2032, with the most significant competitive and commercial development being the potential USPSTF population screening recommendation that would convert the market from clinical indication-based to population health screening scale. The competitive dynamics in the interim period will be defined by the expansion of point-of-care TTG testing into primary care and paediatric settings — a deployment that favours device manufacturers with established primary care distribution relationships over reference laboratory operators whose model depends on specimen shipping rather than point-of-care deployment. The DTC testing segment's continued growth will drive incremental volume but requires ongoing quality assurance investment from DTC laboratory platforms to ensure positive TTG results are appropriately followed by biopsy confirmation — a clinical quality concern that, if not addressed, risks regulatory intervention that would constrain the DTC testing channel's growth trajectory.

IVD platform manufacturers including Bio-Rad, Thermo Fisher, and Inova will compete for hospital laboratory TTG test platform consolidation opportunities — winning the platform installation decisions that determine which manufacturers' TTG test kits are used in each hospital laboratory's centralised testing menu. Platform consolidation decisions are made infrequently — typically every 5–7 years when laboratory instrument contracts are renegotiated — but are high-value wins that generate recurring reagent revenue for the platform's installed-life duration. Manufacturers who invest in clinical evidence generation supporting their TTG test's analytical performance, and who provide health economic analyses demonstrating the cost-effectiveness of their comprehensive celiac testing panels relative to sequential single-analyte testing, will win the platform consolidation decisions that define the long-term competitive structure of the hospital laboratory TTG testing market segment.